What are the candidate groups for pharmacotherapeutic intervention to prevent asthma?

Pediatric Allergy and Immunology, Supplement

Volumn 11, Issue 13, 2000, Pages 41-44

  De Longueville, M ^a  

^a Chemin du Foriest ^*  (Belgium)

Author keywords

Asthma prevention; Children; Pharmacotherapy

Indexed keywords

ALLERGEN; CETIRIZINE; CROMOGLYCATE DISODIUM; HOUSE DUST ALLERGEN; KETOPROFEN; LORATADINE;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; ATOPY; CHRONIC DISEASE; HIGH RISK POPULATION; PATHOGENESIS; POLLEN; PREVALENCE; PRIORITY JOURNAL; SENSITIZATION;

EID: 0033777180     PISSN: 09065784     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3038.2000.00510.x     Document Type: Article

References (16)

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema ISAAC
2. Asthma and wheezing in the first six years of life
3. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
4. Risk factors in early childhood for the development of atopic diseases
5. The development of allergy in high-risk children
6. The natural course of sensitisation and atopic disease in infancy and childhood
7. Towards prevention
8. Allergen avoidance in infancy and allergy at 4 years of age
9. Internation-al Consensus report on diagnosis and management of asthma
10. Asthma: A follow up statement from an international paediatric asthma consensus group
11. Prophylactic treatment with loratadine versus cromolyn sodium in children with mild to moderate perennial asthma
12. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis
13. Prevention of asthma by ketotifen in infants with atopic dermatitis
14. Prevention of asthma with ketotifen in preasthmatic children: A three-year follow-up study
15. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC®